Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/2/2026

1. NKE
2. TRU
3. SPY
4. FICO
5. PECO
6. ACN
7. ON
8. TLT
9. USO
10. SYNA

Go back to Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
(NASDAQ: ACRS) Delayed: 4.41 --0 (-0%)
Previous Close $4.41    52 Week High $33.88 
Open $4.41    52 Week Low $14.12 
Day High $4.41    P/E N/A 
Day Low $4.41    EPS $0.00 
Volume 4,156